German healthcare company Fresenius reported a second-quarter net loss to shareholders of €373 million ($403,64 million) on Wednesday, largely due to its exit from the Vamed hospital provider business. This compares to a profit of €80 million during the same period last year. Reported loss per share was €0.66 compared to a 2023 second-quarter profit of €0.15 per share. Second-quarter EBITDA (earnings before interest, taxes, depreciation, and amortization) before special items increased by 14% to €938 million. Group EBIT before special items increased by 16%, or 15% in constant currency, to €66…